<DOC>
	<DOCNO>NCT00976378</DOCNO>
	<brief_summary>This first time NOX-A12 administer man . The principal aim study obtain safety tolerability data NOX-A12 administer single intravenous ( IV ) dose healthy male female subject . This information , together pharmacokinetic pharmacodynamic data , help establish dos dosage regimen administration suitable subsequent study patient population .</brief_summary>
	<brief_title>NOX-A12 First-in-human ( FIH ) Study</brief_title>
	<detailed_description />
	<criteria>1 . Informed consent sign subject . 2 . Healthy subject age 18 60 year ethnic origin . 3 . Physically mentally healthy subject confirm interview , medical history , clinical examination , laboratory test electrocardiogram . Values reference range assess clinically significant ( NCS ) clinically significant ( CS ) investigator . Individuals present deviate value assess NCS may include . 4 . Subjects willing use contraceptive method time dose 3 month final examination ( condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository ) , females must nonchild bear potential . Nonchild bear potential defined follow : Female subject 50 year age less must surgically sterile postmenopausal ( define least two year post cessation menses follicular stimulate hormone ≥35 mIU/mL serum estradiol ≤25 pg/mL ) , nonlactating negative pregnancy test . Female subject 51 year age old must surgically sterile postmenopausal ( define value follicular stimulate hormone ≥35 mIU/mL , serum estradiol ≤25 pg/mL spontaneous menstruation least one year first dose ) , nonlactating negative pregnancy test . 5 . Body weight defined relation height . Body mass index 19 29 kg/m2 ( extremes include ) . 6 . Calculated creatinine clearance ≥80 mL/min . 7 . Normal lung function ( FVC FEV1 least 80 % predicted value ) screen . 8 . O2 saturation 96 % 100 % ( extremes include ) screen . 9 . Body weight 50 100 kg ( extremes include ) . 10 . The subject cooperative available entire study . 1 . Evidence subject 's medical history medical examination clinically significant hepatic , renal , gastrointestinal , cardiovascular , pulmonary , hematological significant acute chronic abnormality might influence either safety subject absorption , distribution , metabolism excretion active agent investigation . 2 . History general malignant disease . 3 . History renal calculus . 4 . Hypersensitivity drug , atopic eczema , allergic bronchial asthma clinically significant allergic disease ( exclude nonactive hayfever ) . 5 . Intake vitamin A derivative retinoids within 30 day prior start study state subject screening . 6 . Subjects significant history sensitivity natural sunlight artificial light ultraviolet ( UV ) light sunbeds . 7 . History thrombosis . 8 . Laboratory test result outside reference value lay study center , may evidence disease . Positive result HIV1/2 , HCV antibody HBs antigen test . 9 . Subjects abnormality 12lead ECG , opinion investigator , increase risk participate study , QTcB interval &gt; 450 msec ( female ) &gt; 430 msec ( male ) , 2nd 3rd degree atrioventricular block , complete leave bundle branch block , complete right bundle branch block WolffParkinsonWhite Syndrome , define PR &lt; 110 msec , confirm repeat ECG . 10 . Subjects clinically significant illness within 4 week start dose administration determine Investigator . 11 . History relevant heart disorder evidence hyper hypotension ( supine blood pressure systolic &gt; 140 mmHg &lt; 95 mmHg diastolic &gt; 90 mmHg &lt; 65 mmHg screen ) . 12 . Bradycardia Bradyarrhythmia ( pulse rate 3 minute supine rest &lt; 45/min screening ) . 13 . Tachycardia Tachyarrhythmia ( pulse rate 3 minute supine rest &gt; 90/min screening ) . 14 . Acute infection fever within last 4 week state subject screening . 15 . Subjects receive prescribed systemic topical medication within 14 day prior dose administration state subject screening , unless medication interfere study procedure compromise safety assess investigator . 16 . Subjects receive medication ( include St John 's Wort ) know chronically alter drug absorption elimination process within 30 day prior dose administration state subject screening , unless medication interfere study procedure compromise safety assess investigator . 17 . Single use medication ( include OTC ) expressively permit within two week prior schedule admission study ( selfmedication prescription ) state subject screening , unless medication interfere study procedure compromise safety assess investigator . 18 . Abuse alcohol ( equivalent 18 unit per week , 1 unit equivalent one beer ( 330 mL ) one wine ( 150 mL ) one drink ( 40 mL ) ) , caffeine ( equivalent 750 mg per day ) tobacco ( equivalent 10 cigarette day ) . 19 . Alcohol breath test positive screening . 20 . Drug addiction , positive drug screen urine . 21 . Participation clinical investigation blood donation 100 mL comparable blood loss within past 12 week prior start study . 22 . Subjects know suspected ( ) comply study directive , ( ii ) reliable trustworthy , ( iii ) capable understand evaluate information give part formal information policy ( informed consent ) , particular regard risk discomfort would agree expose , ( iv ) precarious financial situation longer weigh possible risk participation unpleasantness may involve . 23 . Subjects inadequate venous access . 24 . Subjects , opinion Investigator , participate study . 25 . Subjects abnormal splenic size . 26 . Increased bleeding risk assess screen base standardized questionnaire bleed history .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>stromal cell-derived factor-1 ( SDF-1 )</keyword>
	<keyword>L-oligonucleotide aptamer</keyword>
	<keyword>Spiegelmer</keyword>
</DOC>